Adial Pharmaceuticals, Inc. Equity Issued in Business Combination, Fair Value Disclosure
Adial Pharmaceuticals, Inc. (ADIL) had Equity Issued in Business Combination, Fair Value Disclosure of $1.73 million as of 2023-12-31, per its 10-K filed 2024-04-01.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure · last filed 2026-03-05
- 2023-12-31: Equity Issued in Business Combination, Fair Value Disclosure $1.73M.
- 2023-09-30: Equity Issued in Business Combination, Fair Value Disclosure $1.73M.
- 2023-06-30: Equity Issued in Business Combination, Fair Value Disclosure $1.73M.
| Period end | Equity Issued in Business Combination, Fair Value Disclosure |
|---|---|
| 2023-12-31 | $1.73M 10-K · filed 2024-04-01 |
| 2023-09-30 | $1.73M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.73M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |